Advisory Board Member Profile 2017
Mariette Boerstoel
|
|
Shire
Sr. VP, Head Global Drug Safety 
Areas of Expertise
Reducing Risk Through Big Data; Driving Innovation with Big Data; Implementation Issues with Big Data
|
Mariette Boerstoel-Streefland, MD, MBA, MS(epi), has been in the pharmaceutical industry for 25 years, most recently as SVP, Head of Global Drug Safety at Shire.
She received her MD at the University of Utrecht in the Netherlands in 1986 and subsequently worked in clinical practice in pediatrics at Utrecht University Medical Centre. In 1989 she moved her career to the pharmaceutical industry, joining Organon, where she had a progressive career in drug safety for 16 yrs, and was Global Head/Vice President for Organon as of 1999. In 2002 she was re-located to New Jersey. In 2005 she joined Mayne Pharma in the position of VP Global Drug Safety and Medical Affairs. After Mayne Pharma’s acquisition by Hospira in April 2007 she moved to Forest Research Institute (now Allergan), where she held the position of Chief Safety Officer and Vice President, Global Drug Safety, covering all of Forest safety functions for all Forest products as well as overseeing the Medical Information function. In 2014 she was recruited to establish and lead a new safety department and function for Baxalta, when it was splitting its Biosciene division of from Baxter. With the subsequent acquisition of Baxalta by Shire in 2016, she was appointed to lead the new safety organization. Mariette received her Masters degree in Pharmaco-Epidemiology from McGill University Montreal and the University of Utrecht in 2001, and her MBA from New York Institute of Technology/Ellis College in July 2007.
|
